Abstract library

2097 results for "in vivo model".
#536 Orexins Exert a Pro-Apoptotic Effect on Neuroendocrine Tumors (NETs) in an Ex Vivo Culture Model of Tissue Slices
Introduction: Ex vivo culture models of tissue slices are suitable to test the effect of antitumor agents in human tumors. The orexins are neuropeptides binding to G protein-coupled receptors (OX1-R and OX2-R), exerting a pro-apoptotic effect in human colon and pancreatic cancer cell lines.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Maxime Palazzo
#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents
Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Franziska Briest
#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models
Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Carleen Cullinane
Authors: Cullinane C, Waldeck K, Kirby L, Eu P, ...
#1127 Zebrafish as a New In Vivo Model to Study Angiogenesis in Neuroendocrine Tumors (NET)
Introduction: Zebrafish is a powerful model to study human diseases, including cancer.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Giovanni Vitale
Keywords: zebrafish, NET
#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model
Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Unrau L, Stahl F, Eggers C, ...
Keywords: pNET, insulinoma, SSTR
#1637 The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models
Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Simona Grozinsky-Glasberg
Keywords: autophagy, mTORi, NET
#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies
Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Andreas Krieg
Authors: Krieg A, Riemer J C, Dizdar L, Mersch S, ...
Keywords: GEP-NEC
#1638 3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuro-Endocrine Tumors (pNETs).
Introduction: The lack of adequate in vitro and in vivo preclinical models has hampered the identification of novel treatment options and the development of personalized therapy selection for pNET patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ilaria Marinoni
#746 Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors
Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Prof.Dr. Volker Fendrich
#502 Bifunctional ShRNAimPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice
Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr F Charles Brunicardi
Authors: Liu S, Wang Z, Shahi K, Rao D, ...